Search

Search Constraints

You searched for: Author/Creator Serfaty, Lawrence

Search Results

1. 820Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b. (December 2014)

2. 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results. (December 2014)

3. ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. (17th January 2022)

4. Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community‐based cohort. Issue 5 (8th June 2022)

5. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Issue 2 (28th October 2015)

7. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Issue 9 (2nd September 2021)

8. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Issue 3 (20th March 2015)

9. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Issue 1 (5th July 2018)

10. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Issue 6 (30th July 2014)